Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in HP-positive gastric MALT lymphoma
NCT06228963Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in gastric mucosa-associated lymphoid tissue lymphoma, sponsored by Fudan University. Started Mar 2024; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
gastric mucosa-associated lymphoid tissue lymphoma
Beyond the preview
Go deeper on NCT06228963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228963.